$904 Million is the total value of Casdin Capital, LLC's 40 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 29.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SRPT | Sell | SAREPTA THERAPEUTICS INC | $122,472,203 | +5.4% | 1,010,330 | -0.5% | 13.56% | +33.4% |
| NTLA | Sell | INTELLIA THERAPEUTICS INC | $37,250,732 | -28.4% | 1,178,075 | -7.6% | 4.12% | -9.3% |
| ALNY | Sell | ALNYLAM PHARMACEUTICALS INC | $35,420,000 | -33.4% | 200,000 | -28.6% | 3.92% | -15.7% |
| EXAS | Sell | EXACT SCIENCES CORP | $31,343,679 | -33.2% | 459,450 | -8.1% | 3.47% | -15.5% |
| PLRX | Sell | PLIANT THERAPEUTICS INC | $27,347,053 | -11.2% | 1,577,108 | -7.2% | 3.03% | +12.4% |
| BPMC | Sell | BLUEPRINT MEDICINES CORP | $18,650,603 | -52.4% | 371,378 | -40.1% | 2.06% | -39.7% |
| FDMT | Sell | 4D MOLECULAR THERAPEUTICS IN | $13,160,414 | -31.9% | 1,033,811 | -3.4% | 1.46% | -13.8% |
| ABCL | Sell | ABCELLERA BIOLOGICS INC | $10,856,593 | -33.3% | 2,360,129 | -6.3% | 1.20% | -15.5% |
| Sell | MAXCYTE INC | $5,896,800 | -72.8% | 1,890,000 | -59.9% | 0.65% | -65.5% | |
| ILMN | Sell | ILLUMINA INC | $3,432,000 | -88.2% | 25,000 | -83.9% | 0.38% | -85.0% |
| Sell | ABSCI CORPORATION | $1,284,703 | -38.2% | 973,260 | -28.9% | 0.14% | -22.0% | |
| OMIC | Sell | SINGULAR GENOMICS SYSTEMS IN | $504,400 | -54.8% | 1,323,885 | -1.6% | 0.06% | -42.9% |
| Exit | SCILEX HOLDING CO | $0 | – | -23,512 | -100.0% | -0.01% | – | |
| SAGE | Exit | SAGE THERAPEUTICS INC | $0 | – | -90,000 | -100.0% | -0.37% | – |
| INCY | Exit | INCYTE CORP | $0 | – | -77,500 | -100.0% | -0.42% | – |
| TWST | Exit | TWIST BIOSCIENCE CORP | $0 | – | -450,000 | -100.0% | -0.80% | – |
| CTLT | Exit | CATALENT INC | $0 | – | -720,000 | -100.0% | -2.73% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BLUEPRINT MEDICINES CORP | 32 | Q3 2023 | 9.6% |
| ALNYLAM PHARMACEUTICALS INC | 32 | Q3 2023 | 9.9% |
| AGIOS PHARMACEUTICALS INC | 27 | Q2 2022 | 12.1% |
| GLOBAL BLOOD THERAPEUTICS IN | 27 | Q2 2022 | 7.1% |
| FATE THERAPEUTICS INC | 26 | Q3 2023 | 8.3% |
| BIOLIFE SOLUTIONS INC | 22 | Q3 2023 | 14.9% |
| CODEXIS INC | 22 | Q3 2023 | 8.1% |
| SAREPTA THERAPEUTICS INC | 21 | Q3 2023 | 13.6% |
| BLUEBIRD BIO INC | 21 | Q4 2020 | 7.8% |
| ILLUMINA INC | 21 | Q3 2023 | 6.0% |
View Casdin Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Absci Corp | May 08, 2023 | 4,448,260 | 4.8% |
| CODEXIS, INC.Sold out | February 14, 2023 | 0 | 0.0% |
| DermTech, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Invitae Corp | February 14, 2023 | 9,038,388 | 3.7% |
| Magenta Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Tango Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Verve Therapeutics, Inc. | February 14, 2023 | 2,290,571 | 3.7% |
| Tenaya Therapeutics, Inc. | December 07, 2022 | 6,427,200 | 9.9% |
| Fulcrum Therapeutics, Inc. | February 11, 2021 | 1,241,176 | 4.5% |
| Gritstone Oncology, Inc.Sold out | February 11, 2021 | 0 | 0.0% |
View Casdin Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-18 |
| SC 13D/A | 2024-04-08 |
| 4 | 2024-03-28 |
| 3 | 2024-03-25 |
| 4 | 2024-03-25 |
| 4 | 2024-03-20 |
| SC 13D/A | 2024-03-20 |
| 4 | 2024-03-06 |
| 4 | 2024-03-06 |
| 13F-HR | 2024-02-14 |
View Casdin Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.